Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 19 record(s)

Req # A-2021-10689

Provide the preparation documents (excluding PowerPoint), meeting summaries and emails related to meetings and communications between PMPRB executives and Janssen over planned reforms to the PMPRB Guidelines from June 1, 2019 to June 9, 2021. Do not include emails related to Zoom, Microsoft Teams or other such mediums for the purposes of conducting the meeting, only the content of the meeting itself.

Organization: Patented Medicine Prices Review Board Canada

3 page(s)
December 2021

Req # A-2021-19383

The daily calendar of meetings, calls and other taskings for Douglas Clark from May 1, 2021 to October 14, 2021.

Organization: Patented Medicine Prices Review Board Canada

24 page(s)
November 2021

Req # A-2021-10661

Provide the preparation documents (excluding PowerPoint), meeting summaries and emails related to meetings and communications between PMPRB executives and Collective Oncology Network for Exchange, Cancer care Innovation, Treatment Access and Education over planned reforms to the PMPRB Guidelines from June 1, 2019 to June 8, 2021. Do not include emails related to Zoom, Microsoft Teams or other such mediums for the purposes of conducting the meeting, only the content of the meeting itself.

Organization: Patented Medicine Prices Review Board Canada

4 page(s)
October 2021

Req # A-2021-11663

A copy of the release package that was disclosed in response to access to information request file number A-2021-007891.

Organization: Patented Medicine Prices Review Board Canada

95 page(s)
June 2021

Req # A-2021-11666

A copy of the PMPRB's 6-page Communication Plan, "Modern and Proactive Communications Strategy", dated February 9, 2021 as previously disclosed in a release package in response to an access to information request.

Organization: Patented Medicine Prices Review Board Canada

6 page(s)
June 2021

Req # A-2021-11668

Copies of the email chain between Michell Levine, Isabel Jaen Raasch, Tanya Potashnik, Douglas Clark, Guillaume Couillard, Riaz Awadia and Elena Lungu having the subject line "Call with IMC this morning", dated December 5, 2019.

Organization: Patented Medicine Prices Review Board Canada

3 page(s)
June 2021

Req # A-2021-03662

Copies of all documentation indicating how excessive revenue payments claimed from pharmaceutical companies were handled and how such payments are processed by the PMPRB.

Organization: Patented Medicine Prices Review Board Canada

32 page(s)
March 2021

Req # A-2020-18433

Copies of the daily calendar meetings, calls and other taskings for Melanie Bourassa-Forcier from June 1, 2019 to November 18, 2020.

Organization: Patented Medicine Prices Review Board Canada

18 page(s)
December 2020

Req # A-2020-18442

A detailed summary of all occasions the PMPRB has used the excessive price penalty for pharmaceutical companies, broken down by date, company penalized, the name of the drug in question, the amount penalized, and a summary of why the price was excessive. Additionally, provide details of how much was collected under the penalty for the past five years and how the money gained from the penalties was used.

Organization: Patented Medicine Prices Review Board Canada

2 page(s)
December 2020
Date modified: